EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Solesence, Inc. (SLSN) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Solesence, Inc. $0.43, price $0.81, upside -46.9%, quality 29 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Consumer Defensive · US · ISIN US6300791018

SI Solesence, Inc. logo Thin data Sep 23, 2026

Solesence, Inc.

SLSN · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.4300 · Strongly overvalued (−47%)
!Quality 29/100
!Expensive Growth (revenue 3y +18.5 %/yr)
!Loss over the last twelve months · -5.3% net margin (TTM) · fiscal year 2025 2.9%
!Moderate debt · negative free cash flow
!Trails peers (1/11)
!Narrow moat 13/100
!Evidence only low, so the estimate is less certain
Watch Solesence, Inc. Common Stock for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$5.21 $0.6400 Fair Value $0.4300 Apr 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

18‑month range $0.6400 – $5.21 · fair‑value band $0.3200 – $0.5400 · the $0.8100 price screens above the $0.4300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Solesence, Inc. Common Stock in your weekly email

Every Wednesday you see whether Solesence, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Solesence, Inc., a science-driven company, provides engineered materials, formulation development, and commercial manufacturing services in the United States. The company engages in the manufacture and supply of surface engineered zinc oxide and titanium dioxide ingredients.

Show more

Solesence, Inc., a science-driven company, provides engineered materials, formulation development, and commercial manufacturing services in the United States. The company engages in the manufacture and supply of surface engineered zinc oxide and titanium dioxide ingredients. It also provides skin care formulations with mineral-based UV protection enabled by proprietary active pharmaceutical ingredients; and skin health products, such as sunscreens and daily care products. The company sells products in various markets, including medical diagnostics, architectural coatings, industrial coating applications, abrasion-resistant additives, and plastics additives applications. It serves skin health, beauty, and wellness sectors. The company was formerly known as Nanophase Technologies Corporation and changed its name to Solesence, Inc. in March 2025. Solesence, Inc. was incorporated in 1989 and is headquartered in Romeoville, Illinois.

Stock analysis

Solesence, Inc. Common Stock (SLSN) currently trades at $0.8100, while our model-based Fair Value estimate is $0.4300, implying the stock looks roughly 88.4% overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $0.6500 per share, and 1 of the 15 models we run sit above the $0.8100 price.

Bear case: the Asset-Based group reads lowest at $0.1700, and 14 of the 15 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.3200 (bear) to $0.5400 (bull), the price of $0.8100 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Consumer Defensive sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Solesence, Inc. Common Stock reported revenue of $62.1M in FY2025 versus $29.5M in FY2021, a compound +20.5%/yr. Reported net income was $1.8M in FY2025, compounding −6.3%/yr from FY2021.

Key figures

Market cap $57.2M · P/E ratio 129.0 · P/S ratio 3.72 · EPS (TTM) $−0.0500 · Net margin 2.9% · Return on equity −18.6% · Return on assets (EBIT) 1.0% · Operating margin 0.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).

What moves the price

The share trades about 81% below its 52-week high and 27% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at −14% fair-value upside, at −47%, SLSN screens richer than that median.

Fair Value models

Bear $0.3200 Fair Value $0.4300 Bull $0.5400
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV $0.0100 $0.0300 $0.0400 70
Residual Income $0.2000 $0.2100 $0.2300 68
Owner Earnings $0.0900 $0.3000 $0.6600 66
All 15 models by family
DCF Models
Owner Earnings $0.0900 $0.3000 $0.6600 66
Earnings-Based
Graham-Dodd $0.1700 $1.20 $1.69 60
Lynch FV $0.3700 $0.5200 $0.6800 58
PEG = 1.0 $0.3700 $0.5200 $0.6800 55
EPV $0.0100 $0.0300 $0.0400 70
Multiples
P/E Multiple $0.3200 $0.4300 $0.5400 63
P/S Multiple $0.3200 $0.4300 $0.5400 58
P/B Multiple $0.3200 $0.4300 $0.5400 55
EV/EBIT $0.1000 $0.1800 $0.2600 63
EV/EBITDA $0.1300 $0.2200 $0.3100 65
EV/Revenue $0.0700 $0.1600 $0.2500 51
Asset-Based
NCAV (Graham) $0.1200 $0.1700 $0.2500 54
Economic Profit
Residual Income $0.2000 $0.2100 $0.2300 68
ROIC Compounder $0.0100 $0.0300 $0.0400 66
Growth Earnings
Growth-Adj P/E $0.4600 $0.6500 $0.8500 65

Open the full fair value analysis →

Notify me when SLSN reaches fair value

Put SLSN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 29/100

Of which business quality 32 · Market factors (momentum, volatility) 14

Profitability 51
Margins and returns on capital today
Quality Growth 36
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 25
Balance sheet, leverage, solvency risk
Investment 40
Disciplined investing over empire-building
Low Volatility 20
Calm price path (market factor)
Momentum 16
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 50
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+18.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.5%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−12.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−12.9%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 3%

SLSN screens 88% overvalued. Compare with Colgate-Palmolive Company →

Compare Solesence, Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 251 stocks

Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −47% · Bottom 25%
Profitability
Return on assets −2% · Bottom 25%
Net margin (TTM) −5% · Bottom 25%
Operating margin (TTM) 1% · Bottom 25%
Growth and dividend
Revenue growth −25% · Bottom 25%
Balance sheet
Debt / equity 0.60× · Highest 25%

Valuation Multiplesvs Household & Personal Products median · lower = cheaper

P/E (TTM) 129.0× · Priciest 25%
P/B 3.24× · Priciest 25%
P/S (TTM) 1.03× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 33
FUTURE (revenue growth)0 · sector 8
PAST (return on equity)0 · sector 27
HEALTH (low debt)70 · sector 98
DIVIDEND (yield)0 · sector 55

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Colgate-Palmolive Company CL $85.93 $55.95 −35%
Hindustan Unilever Limited HINDUNILVR ₹1,950 ₹775.25 −60%
Kenvue Inc KVUE $17.86 $12.73 −29%
Kimberly-Clark Corporation KMB $97.70 $83.93 −14%
Henkel AG HEN €68.50 €80.96 +18%
The Estée Lauder Companies Inc EL $98.83 $27.22 −72%
Church & Dwight Co CHD $96.02 $65.12 −32%
Beiersdorf Aktiengesellschaft, BEI €78.18 €68.95 −12%
Puig Brands, S.A PUIG €17.56 €19.32 +10%
The Clorox Company CLX $87.15 $104.53 +20%

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Solesence, Inc. Common Stock · Fair Value
$0.4300 −88%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Solesence, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/SLSN

Frequently asked questions

Is Solesence, Inc. (SLSN) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.4300 versus a price of $0.8100, about −47% upside (overvalued).
What is the fair value of SLSN?
Our model-based fair value for Solesence, Inc. Common Stock is $0.4300 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.8100.
What is the quality score of SLSN?
Solesence, Inc. Common Stock has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Solesence, Inc. (SLSN)?
Our model-based price target is the fair value of $0.4300 (as of Sep 23, 2026) from 15 valuation models. Cautious scenario $0.3200, optimistic scenario $0.5400. It is a calculation from audited fundamentals, not an analyst target.
What is the Solesence, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $0.4300, about −47% upside versus a price of $0.8100 (overvalued). Cautious scenario $0.3200, optimistic scenario $0.5400. The calculation is refreshed regularly with new filings.
What is the revenue of Solesence, Inc. (SLSN)?
Solesence, Inc. Common Stock reported trailing-twelve-month revenue of about $55.4M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Solesence, Inc. (SLSN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Solesence, Inc. Common Stock it is $0.4300 per share (as of Sep 23, 2026), against a price of $0.8100. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Solesence, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Sep 23, 2026, SLSN trades above its calculated fair value: price $0.8100, fair value $0.4300, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SLSN?
No. The price is what the market pays today ($0.8100); the fair value is what the company's own numbers justify ($0.4300). For Solesence, Inc. Common Stock the two are $0.3800 per share apart. That gap is exactly why we show both numbers side by side.
How much is Solesence, Inc. Common Stock worth?
The market values Solesence, Inc. Common Stock at about $57.2M (market capitalisation, as of Sep 23, 2026). Per share that is $0.8100; our models calculate a fair value of $0.4300 per share.
What do the bullish and bearish scenarios say about SLSN?
Our models span a range for Solesence, Inc. Common Stock: cautious scenario $0.3200, base $0.4300, optimistic $0.5400 per share (as of Sep 23, 2026, price $0.8100). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SLSN?
Solesence, Inc. Common Stock trades at a price-to-earnings ratio of 129.0 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.4300 is built from several models across several years. Other multiples: P/B 3.2, P/S 1.0.
How solid is the balance sheet of Solesence, Inc. (SLSN)?
Balance-sheet figures for Solesence, Inc. Common Stock (as of Sep 23, 2026): return on equity −18.6%, debt of 0.60 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is SLSN from its 52-week high?
Solesence, Inc. Common Stock trades at $0.8100, about 81% below its 52-week high of $4.36 and 27% above the low of $0.6400 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4300 is for.
Which stocks are comparable to Solesence, Inc. Common Stock?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, Kenvue Inc, Kimberly-Clark Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Solesence, Inc. Common Stock stock attractive at the current price?
The data as of Sep 23, 2026: price $0.8100, calculated fair value $0.4300 (−47%), Quality Score 29/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SLSN calculated?
We run Solesence, Inc. Common Stock through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.4300, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Solesence, Inc. Common Stock itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Solesence, Inc. (SLSN)?
The closing price on Sep 24, 2026 was $0.8100. Our model-based fair value is $0.4300, about −47% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Solesence, Inc. Common Stock right now?
The price sits above even our optimistic bull case ($0.5400). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Solesence, Inc. Common Stock

How large is the market capitalisation of Solesence, Inc. (SLSN)?
The market capitalisation of Solesence, Inc. Common Stock is $57.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Solesence, Inc. (SLSN)?
The price-to-sales ratio of Solesence, Inc. Common Stock is 3.72 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Solesence, Inc. (SLSN)?
Earnings per share at Solesence, Inc. Common Stock are $−0.0500 (price ÷ EPS = P/E 129.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Solesence, Inc. (SLSN)?
The net margin of Solesence, Inc. Common Stock is 2.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Solesence, Inc. (SLSN)?
The return on equity (ROE) of Solesence, Inc. Common Stock is −18.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Solesence, Inc. (SLSN)?
On an EBIT basis the return on assets of Solesence, Inc. Common Stock is 1.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Solesence, Inc. (SLSN)?
The operating margin of Solesence, Inc. Common Stock is 0.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Solesence, Inc. (SLSN)?
Revenue at Solesence, Inc. Common Stock is growing −24.7% versus a year earlier (3y avg +18.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Solesence, Inc. (SLSN)?
Earnings per share at Solesence, Inc. Common Stock are growing −93.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Solesence, Inc. (SLSN) generate?
The free cash flow of Solesence, Inc. Common Stock is −$10.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Solesence, Inc. (SLSN) carry?
The net debt of Solesence, Inc. Common Stock is $23.0M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Solesence, Inc. Common Stock in the live analysis

One click puts Solesence, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.